Ronald Goode - Hikma Pharmaceuticals Non-Executive Independent Director
| HIK Stock | EUR 148.00 1.00 0.67% |
Director
Dr. Ronald L. Goode, Ph.D., is NonExecutive Independent Director of Hikma Pharmaceuticals Plc. Rons executive career focused on the international pharmaceutical industry, including roles as Chief Executive, President of International Operations at Searle, Vice President of Clinical and Scientific Affairs at Pfizer, and adviser to companies in the pharmaceutical industry. since 2006.
| Age | 73 |
| Tenure | 18 years |
| Professional Marks | Ph.D |
| Web | https://www.hikari.co.jp |
Hikma Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0231 % which means that it generated a profit of $0.0231 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1885 %, meaning that it generated $0.1885 on every $100 dollars invested by stockholders. Hikma Pharmaceuticals' management efficiency ratios could be used to measure how well Hikma Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 1 records | DIRECTOR Age | ||
| Shaun McCabe | TRAINLINE PLC LS | 49 | |
Management Performance
| Return On Equity | 0.19 | |||
| Return On Asset | 0.0231 |
Hikma Pharmaceuticals PLC Leadership Team
Elected by the shareholders, the Hikma Pharmaceuticals' board of directors comprises two types of representatives: Hikma Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hikma. The board's role is to monitor Hikma Pharmaceuticals' management team and ensure that shareholders' interests are well served. Hikma Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hikma Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Fadi Nassar, Corporate Vice President - Active Pharmaceutical Ingredients | ||
| Bassam Kanaan, Chief Strategy & Corporate Development Officer | ||
| Khalid Nabilsi, CFO | ||
| Hussein Arkhagha, General Counsel | ||
| Susan Ringdal, Vice President - Corporate Strategy and Investor Relations | ||
| Pamela Kirby, Non-Executive Independent Director | ||
| John Castellani, Non-Executive Independent Director | ||
| Brian Hoffman, President and Chief Executive of - Generics Division | ||
| Ali AlHusry, Non-Executive Director | ||
| Jochen Gann, Non-Executive Director | ||
| Hideaki Wada, CEO Pres | ||
| Koh Gidoh, GM MD | ||
| Peter Speirs, Company Secretary | ||
| Patrick Butler, Non-Executive Independent Director | ||
| Said Darwazah, Chairman of the Board, Chief Executive | ||
| Michael Raya, President and CEO, USA | ||
| Ronald Goode, Non-Executive Independent Director | ||
| Bryan Hotston, CIO | ||
| Sigurdur Olafsson, CEO | ||
| Yasumitsu Shigeta, Chairman Founder | ||
| Breffni Byrne, Non-Executive Independent Director | ||
| Nina Henderson, Non-Executive Independent Director | ||
| Cynthia Schwalm, Independent Non-Executive Director | ||
| Ragheb AlShakhshir, Corporate Vice President - Research & Development | ||
| Michael Ashton, Non-Executive Independent Director | ||
| Majda Labadi, Corporate Vice President - Human Resources | ||
| Ibrahim Jalal, Senior Corporate Vice President - Technical Affairs | ||
| Riad Mishlawi, EU Vice President and Global Head - Injectables | ||
| Robert Pickering, Senior Non-Executive Independent Director | ||
| Mazen Darwazah, Executive Vice Chairman of the Board; President and CEO of MENA and Emerging Markets | ||
| Masato Takahashi, Director Director |
Hikma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hikma Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.19 | |||
| Return On Asset | 0.0231 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.09 % | |||
| Current Valuation | 7.67 B | |||
| Shares Outstanding | 44.31 M | |||
| Shares Owned By Insiders | 57.06 % | |||
| Shares Owned By Institutions | 14.55 % | |||
| Price To Earning | 23.96 X | |||
| Price To Book | 1.55 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hikma Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for Hikma Stock analysis
When running Hikma Pharmaceuticals' price analysis, check to measure Hikma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hikma Pharmaceuticals is operating at the current time. Most of Hikma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hikma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hikma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hikma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |